Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables
Article first published online: 18 DEC 2013
Copyright © 2013 Wiley Periodicals, Inc.
Journal of Clinical Apheresis
How to Cite
Abuabdou, A., Rosenbaum, E. R., Usmani, S. Z., Barlogie, B. and Cottler-Fox, M. (2013), Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables. J. Clin. Apheresis. doi: 10.1002/jca.21313
- Article first published online: 18 DEC 2013
- Manuscript Accepted: 27 NOV 2013
- Manuscript Revised: 26 OCT 2013
- Manuscript Received: 28 JUN 2012
- National Cancer Institute, National Institutes of Health. Grant Number: CA 55813
Mobilization regimens for CD34+ cells have generally been judged successful based on the number of cells collected without evaluating mobilization separately from collection. Using retrospective data for patients who collected CD34+ cells on Total Therapy protocols 3a/3b (VTD-PACE) and Total Therapy 4/5 using a novel regimen that added low dose melphalan to VTD-PACE (MVTD-PACE), we analyzed mobilization and collection variables separately. A significant difference favoring MVDT-PACE was found in mean CD34+ cells/µL on day 2 of collection and in mean ratio of CD34+ cells/µL on day 2 to day 1. However, because apheresis variables and growth factor dose during collection were manipulated to optimize individual collections, the two regimens were not significantly different when the mean total CD34+ cells ×106/kg collected was compared. Thus, when evaluating a chemotherapy regimen or new growth factor for mobilization, it is important to realize that total CD34+ cells collected is dependent on both mobilization and collection variables. J. Clin. Apheresis, 2013. © 2013 Wiley Periodicals, Inc.